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Objective: The purpose of this study was to evaluate the effectiveness of mature red cell and
reticulocyte parameters under three conditions: iron deficiency anemia, anemia of chronic
disease, and anemia of chronic disease associated with absolute iron deficiency.
Methods: Peripheral blood cells from 117 adult patients with anemia were classified accord-
ing  to iron status, and inflammatory activity, and the results of a hemoglobinopathy
investigation as: iron deficiency anemia (n = 42), anemia of chronic disease (n = 28), anemia
of  chronic disease associated with iron deficiency anemia (n = 22), and heterozygous  tha-
lassemia (n = 25). The percentage of microcytic red cells, hypochromic red cells, and levels of
hemoglobin content in both reticulocytes and mature red cells were determined. Receiver
operating characteristic analysis was used to evaluate the accuracy of the parameters in
differentiating between the different types of anemia.
Results: There was no significant difference between the iron deficient group and anemia
of  chronic disease associated with absolute iron deficiency in respect to any parameter.
The  percentage of hypochromic red cells was the best parameter to discriminate anemia
of  chronic disease with and without absolute iron deficiency (area under curve = 0.785; 95%
confidence interval: 0.661–0.909, with sensitivity of 72.7%, and specificity of 70.4%; cut-off
value 1.8%). The formula microcytic red cells minus hypochromic red cells was very accu-
rate in differentiating iron deficiency anemia and heterozygous  thalassemia (area under
curve = 0.977; 95% confidence interval: 0.950–1.005; with sensitivity of 96.2%, and specificity
of  92.7%; cut-off value 13.8).
Conclusion: The indices related to red cells and reticulocytes have a moderate performance
in  identifying absolute iron deficiency in patients with anemia of chronic disease.©  2014 Associac¸ão Brasileira de Hematologia, Hemoterapia e Terapia Celular. Published
by Elsevier Editora Ltda. All rights reserved.
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ew automated blood cell analyzers can provide information
bout individual cell characteristics, including the hemoglobin
ontent of reticulocytes and mature red blood cells, and per-
entages of microcytic red cells and hypochromic red cells.
hese new parameters have been used in the diagnosis of
ron deficiency anemia (IDA),  thalassemia (-thal) carriers,1–3
nd anemia of chronic disease (ACD).4,5 The differentiation
etween these three conditions is very important as the clin-
cal approach is unique to each particular condition.
As reticulocytes have a normal life span of one to two days,
nformation concerning the hemoglobin content of young red
ells is a good measurement of the iron availability and an
arly marker of iron deficient erythropoiesis.6 Reticulocyte
emoglobin equivalent (Ret-He) reflects real-time informa-
ion on the synthesis of young red cells in the bone marrow.
ther available parameters are the percentage of red cells with
b content equivalent to or less than 17 pg (%HypoHe), and
he percentage of red cells with a volume of less than 60 fL
%MicroR),1 which corresponds to a sub-population of mature
ed cells exhibiting evidence of insufficient iron content.
A mathematical formula using %MicroR and %HypoHe
MHe), proposed by Urrechaga et al.,7 tested discriminant
ndices in healthy individuals, -thal and IDA patients; its sen-
itivity was 97.4% and specificity was 97.1% in differentiating
-thal from mild IDA.
Anemia associated with chronic inflammation, infection
r malignancy is the most common anemia in hospitalized
atients. Although stainable iron is present in the bone mar-
ow, elevated levels of inflammatory cytokines interfere in
rythropoiesis, leading to a hyporegenerative anemia and
efective iron incorporation into red cell progenitors. Reduced
oncentrations of circulating iron and normal or increased
ron stores characterize a state of functional iron deficiency.8
Anemia of inflammation can be associated with abso-
ute iron deficiency (ADC combi), generally in patients with
nflammatory disease and chronic blood loss. Differentiation
etween ACD and ACD combi is clinically important, but in
he clinical practice this differentiation is difficult when using
onventional biomarkers such as ferritin concentration and
ransferrin saturation.9 The soluble transferrin receptor/log
erritin ratio may be useful in distinguishing ACD from ACD
ombi.10
The aim of the study was to analyze the effectiveness of
ew laboratory parameters related to mature red blood cells
nd reticulocytes in differentiating three conditions related to
ron deficiency: IDA, ACD and ACD combi. Indeed, the perfor-
ance of the parameters will be tested to distinguish IDA from
-thal, two common causes of microcytic anemia.
ethods
his project was approved by the Ethics Committee of the
aculdade de Ciências Médicas da Universidade Estadual de
ampinas (UNICAMP), São Paulo, Brazil. All samples were
elected from routine blood collections and so informed con-
ent was waived. 1 4;3  6(6):424–429 425
Peripheral blood samples from 117 adult patients with ane-
mia  (Hb < 12.0 g/dL for women and Hb < 14.0 g/dL for men) were
selected from the routine workload. Blood analysis had been
requested by general practitioners mostly to investigate ane-
mia.
Patients were classified according to iron status analysis
(commercial kits from Roche Diagnostics, Germany): IDA when
serum iron (SI) levels were <45 mg/dL for men  and <30 mg/dL
for women, transferrin saturation <15% and serum ferritin
<30 g/L for men  and <13 g/L for women.
Patients were classified as ACD when SI levels were normal
or less than normal (40–160 mg/dL and 30–160 mg/dL for men
and women, respectively), transferrin saturation was normal
or less than normal (30–50%), serum ferritin levels were nor-
mal  or high (30–400 g/L and 13–150 g/L for men  and women,
respectively) and C-reactive protein >5 mg/dL (Tina-Quant C-
Reactive Protein, Roche Diagnostics, Germany).
Soluble transferrin receptor (sTfR) levels (Roche Diagnos-
tics, Germany) were measured in all samples, and the sTfR/log
ferritin ratio was used to identify iron deficiency in patients
with ACD. Patients with ACD showing sTfR/log ferritin >2.06 or
sTfR >3.71 g/mL (cut-off values indicative of iron deficiency
in our laboratory) were classified as ACD combi.
Twenty-six patients had diagnoses of -thal according to
the level of hemoglobin A2 determined by high performance
liquid chromatography (HPLC-Variant II – Hemoglobin Testing
System, Bio-Rad Laboratories, Inc., CA, USA).
Patients with -thal associated with other kinds of anemia,
patients with reticulocytosis or pancytopenia, individuals that
had received transfusions within the previous three months,
and patients on iron replacement therapy were excluded from
the study.
A control group was composed of apparently healthy
individuals with no clinical signs or symptoms of disease,
including acute inflammatory/infection, and with normal
hematologic findings, and C-reactive protein <5 mg/L. The
healthy individuals were students or laboratory staff, all
of whom had donated blood samples on a voluntary
basis.
Determination of red cell and reticulocyte parameters was
performed using a Sysmex XE-5000 automated hematological
analyzer (Sysmex, Kobe, Japan), which provided the following
parameters: Ret-He, %MicroR, hemoglobin content of red cells
obtained from optical counting (RBC-He), and %HypoHe. The
MHe  index was calculated as %MicroR − %HypoHe.7
The Mann–Whitney test was applied to compare the
groups. A receiver operator characteristic (ROC) curve was
used to evaluate the accuracy of the parameters to differ-
entiate between the different types of anemia. The level of
significance was set at a p-value < 0.05. Data were analyzed
using SPSS for Windows, Version 13.0 (SPSS Inc., Chicago, IL,
USA).
ResultsAccording to adopted criteria, individuals were classi-
fied as: IDA = 42 patients, -thal = 25 individuals, ACD
combi = 22 patients, ACD = 28 patients and control group = 54
individuals.
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Table 1 – Demographic characteristics and hematological data for patients and control group.
Parameter IDA -Thal ACD combi ACD CG
n 42 25 22 28 54
Age (years)
Median 42.0a,b 54.0a 65.6b 51.0 41.0
Range 16.0–82.0 15.0–76.0 20.0–81.0 17.0–82.0 16.0–75.0
Gender (%)
Male/female 26.2/73.8 66.7/33.3 42.9/57.1 63.6/36.4 35.8/62.3
Hb (g/dL)
Median 10.1 12.0 9.9 9.5 13.7
Range 6.2–13.6 6.9–14.7 7.3–12.2 6.6–12.8 12.0–16.1
MCV (fl)
Median 75.2 65.7 74.4 81.1 87.9
Range 61.2–79.6 58.4–70.8 58.5–88.9 61.4–95.2 80.5–94.8
MCH (pg)
Median 22.5 20.4 24.2 26.8 29.1
Range 17.0–26.1 18.4–24.4 18.4–28.9 19.6–32.0 25.4–32.2
RDW (%)
Median 16.4 16.3 16.6 15.5 13.2
Range 13.4–21.0 14.0–19.0 13.7–28.2 13.3–25.6 12.0–15.5
IDA: iron deficiency anemia; -thal: heterozygous beta thalassemia; ACD combi: anemia of chronic disease associated with absolute iron
deficiency; ACD: anemia of chronic disease; CG: control group; Hb: hemoglobin; MCV: mean cell volume; MCH: mean cell hemoglobin; RDW: red
cell distribution width.
a p = 0.030.
b p = 0.023.
Table 1 describes the demographic characteristics and lab-
oratorial data of the patients and control group, and Table 2
shows the iron status measurements used to classify the
patients in the different groups.
As expected the -thal group had the highest %MicroR
(Table 3). The %HypoHe was also higher in the -thal group
when compared to other groups, except for IDA patients.
Table 2 – Biochemical data.
Parameters IDA -Thal 
n 42 25 
SI (mg/dL)
Median 24.5 94.0 
Range 7.0–73.0 49.0–224.0 
TS (%)
Median 6.1 31.9 
Range 1.5–15.5 22.4–68.2 
SF (g/L)
Median 8.2 224.5 
Range 3.2–23.4 66.8–1619.0 
sTfR (g/mL)
Median 9.4 7.4 
Range 1.4–28.8 2.6–25.5 
sTfR/log ferritin
Median 10.4 2.6 
Range 1.9–40.9 1.3–10.9 
IDA: iron deficiency anemia; -thal: heterozygous beta thalassemia; AC
deficiency; ACD: anemia of chronic disease; CG: control group; SI: serum
transferrin receptor.However, as the microcytic cells were more  abundant in the
-thal group, when these two parameters were associated in
the MHe index, the difference became more  evident and sta-
tistically significant.
The Mann–Whitney test showed no significant difference
between the IDA and ACD combi groups in respect to all
parameters. When the ACD and ACD combi groups were
ACD combi ACD CG
22 28 54
23.5 28.0 100.0
12.0–99.0 9.0–98.0 49.0–185.0
9.2 11.6 29.5
4.5–25.7 3.0–42.2 17.6–50.1
254.5 163.7 59.6
27.8–2000.0 42.1–2000.0 19.7–407.9
7.0 2.7 2.4
3.5–22.4 0.5–6.2 1.6–3.8
3.4 1.1 1.3
1.3–9.6 0.2–3.8 0.8–2.2
D combi: anemia of chronic disease associated with absolute iron
 iron, TS: transferrin saturation; SF: serum ferritin; sTfR: soluble
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Table 3 – Reticulocyte and red cell indices for patient and control groups.
Parameters IDA -Thal ACD combi ACD CG
n 42 25 22 28 54
Ret-He (pg)
Median 25.2 23.0 26.0b 29.7c 35.1
Range 16.9–32.6 21.1–30.2 19.2–37.0 21.0–39.5 31.0–39.2
RBC-He (pg)
Median 23.4a 21.9 26.4b 28.7c 31.8
Range 16.7–35.3 18.8–26.3 19.5–30.5 20.8–34.7 28.0–34.2
HypoHe (%)
Median 6.2 9.4 4.4b 1.4c 0.2
Range 0.4–44.5 1.4–20.4 1.1–31.5 0.3–15.3 0.1–0.8
MicroR (%)
Median 13.5a 29.2 14.2b 5.55c 1.4
Range 0.4–48.5 19.3–54.2 0.6–59.0 1.2–48.9 0.5–4.0
MHe
Median 5.8a 23.0 7.2b 4.05c 1.15
Range −9.8 to 22.2 8.1–34.6 0.0–27.5 0.5–36.3 0.3–3.7
IDA: iron deficiency anemia; -thal: heterozygous beta thalassemia; ACD combi: anemia of chronic disease associated with absolute iron
deficiency; ACD: anemia of chronic disease; CG: control group; Ret-He: reticulocyte hemoglobin content; RBC-He: red blood cell hemoglobin
content; HypoHe: percentage of hypochromic red cells; MicroR: percentage of hypochromic red cells; MHe: MicroR − HypoHe index.
Mann–Whitney test was applied for comparison between groups.
a p < 0.01 (IDA × -thal).
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ompared, the RBC-He and Ret-He were significantly lower
or the ACD combi group (p-value = 0.016 and p-value = 0.003,
espectively). Meanwhile, the %MicroR, %HypoHe and the
alue of MHe  were significantly higher in the ACD combi group
p-value = 0.001, p-value = 0.003 and p-value = 0.014, respec-
ively).
Although the ACD group had sTFR/log ferritin values below
he cut-off limit indicative of iron deficiency, the Ret-He and
BC-He values were significantly reduced when compared to
he control group. However, the %HypoHe, %MicroR and MHe
ere higher (p-value < 0.001 for all).
The best test to differentiate IDA from -thal was the MHe
ndex (area under curve – AUC: 0.977; 95% confidence interval
95% CI]: 0.950–1.005). Values below the cut-off of 13.8 showed
 sensitivity of 96.2% and specificity of 92.7% in identifying IDA
atients. A good performance was seen for the %MicroR (AUC:
.886; CI 95%: 0.810–0.963), and values <25.0% gave sensitivity
f 84.6% and specificity of 78.0% in detecting iron deficiency.
When the ROC curve was applied to the ACD and ACD
ombi groups, the best performance was seen with the
HypoHe parameter, although with a moderate AUC value
AUC: 0.785; 95% CI: 0.661–0.909; sensitivity 72.7%, and speci-
city 71.4%; cut-off: 1.8%).
The best parameter to distinguish IDA from ACD was
he %HypoHe (AUC: 0.835; 95% CI: 0.737–0.933). A value for
HypoHe < 2.45% had a sensitivity of 75.4% and specificity of
0.4% in identifying ACD. The AUCs were lower for RBC-He
AUC: 0.809; 95% CI: 0.696–0.922), Ret-He (AUC: 0.780; 95% CI:
.661–0.899), and %MicroR (AUC: 0.785; 95% CI: 0.662–0.908).
The capacity of the tests in discriminating IDA from ACD
ombi was not satisfactory as the AUC was lower than 0.700
or all parameters.Discussion
The diagnostic performance of reticulocyte parameters has
been tested by many  authors, especially for the diagnosis of
iron deficiency in patients submitted to dialysis.6,10,11 Mea-
surement of the reticulocyte content is helpful in detecting
the earliest stages of iron deficiency, prior to the development
of anemia.6,12,13 The reduction in reticulocyte hemoglobin has
been observed in other conditions besides iron deficiency,
such as in hemoglobinopathies.14,15
The effectiveness of using reticulocyte parameters to diag-
nose IDA and ACD has been tested in other studies.2,8,16 In
a recent study with geriatric patients, the authors concluded
that Ret-He does not perform better than the classic indices,
such as mean cell hemoglobin and mean cell hemoglobin
concentration in differentiating between IDA and ACD.5 Our
results show that, although the Ret-He value was lower in
IDA than ACD, the accuracy of the test to distinguish both
types of anemia was moderate, and lower than using the
%HypoHe. A potential utility of Ret-He was demonstrated
in a study with patients with chronic rheumatic disease
and anemia. The predictive value of Ret-He was tested in
response to oral iron therapy, and according to the authors,
the findings support the role of Ret-He as a marker for iron
responsiveness.17
Additional red blood cell parameters, besides Ret-He, have
been tested, such as the %MicroR, and %HypoHe, and other
indices generated by combining them.18 The results regarding
the differentiation between IDA and -thal are promising,
although the optimum cut-off point has varied according to
study population and criteria adopted to classify anemia.18,19
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The MHe  index was first proposed and tested by Urrechaga
et al.16 The performance of this index was better (sensitiv-
ity 98.0% and specificity 95.9) than other published indices.
The authors suggest that samples with MHe values >11.5
can be chosen for further analysis to confirm the diagnosis
of -thal. These data are coincident with our results. The
MHe  index showed the best performance in discriminating
IDA from -thal, although the cut-off value is different from
the value described by Urrechaga et al.,16 probably because
we did not separate patients according to the severity of
anemia.
As far as we  know, no other reports exist about
the efficiency of other red cell parameters in patients
with anemia of inflammation associated with absolute
iron deficiency. The clinical utility of the determination
of the %Hypo has long been recognized in differentiat-
ing between iron-deficient and iron-sufficient patients with
chronic kidney disease who  receive erythropoietin stimulating
agents.20
The sTfR/log ferritin ratio values were calculated to identify
iron deficiency in patients with ACD. The measurement of sTfR
has been considered a good indicator of functional iron status
as it does not suffer the influences of systemic inflammation
unlike SI, transferrin, and ferritin measurements.21,22 Thus,
when there is a reduction of functional iron, transferrin recep-
tor synthesis is stimulated, as was observed in our results. Iron
deficiency is characterized by an increase in sTfR levels and
low ferritin values, while in anemia of inflammation, transfer-
rin receptor levels are only slightly affected and serum ferritin
is greatly increased.23 In the clinical practice this differentia-
tion is important because iron supplementation is beneficial
for ACD combi, but may be deleterious for ACD patients.
According to our results the best parameter to distinguish ACD
combi from ACD was the %HypoHe even though the sensitiv-
ity and specificity were moderate, followed by %MicroR. It is
interesting to note that there were no differences between the
IDA and ACD combi groups for any test, as opposed to differ-
ences observed when ACD was compared with IDA. In fact,
the absolute iron deficiency associated to ACD increases the
number of microcytic and hypochromic red cells, developing
cell features similar to IDA. ACD patients showed evidence
of reduced iron availability for erythropoiesis, but the dis-
turbance of the iron metabolism in functional iron deficiency
was less remarkable than in the association of ACD with
IDA.
In practical terms the incorporation of new cellular
indices can speed up diagnosis of IDA, -thal and ACD, and
consequently target more  quickly and more  precisely the
subsequent confirmatory exams in order to introduce the
appropriate treatment. On the other hand, the difficulty in
identifying absolute iron deficiency in patients with inflam-
matory conditions remains. Therefore, the challenge persists,
and other studies are needed to find a parameter with value
in clinical decision making.Conflicts  of  interest
The authors declare no conflicts of interest.
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